AtriCure (NASDAQ:ATRC) is one of the most promising mid-cap healthcare stocks under $50. On December 16, J.P. Morgan analyst Lilia-Celine (Lily) reiterated her bullish stance on AtriCure (NASDAQ:ATRC). The analyst assigned a Buy rating and raised her price target on the stock from $42 to $48 per share. According to Lily’s estimates, the stock offers an upside potential of over 17% for investors. gpointstudio/Shutterstock.com AtriCure (NASDAQ:ATRC) recently announced the successful completion of its fir ...

Key Takeaways ATRC treated its first patients with a dual-energy PFARFA platform, marking a key innovation step.ATRC pairs PFA with advanced RFA to speed procedures and give surgeons more flexible ablation options.ATRC's initial cases achieved complete box lesions in under 60 seconds with acute electrical isolation.AtriCure (ATRC) recently took a major step forward in surgical ablation innovation with the first patients successfully treated using its new dual-energy platform. The system uniquely pairs Pulse ...